Market Chatter: Novo Nordisk Spends Double on US Advertising for GLP-1 Drugs Than Lilly
MT Newswires Live
Jan 28
Novo Nordisk (NVO) spent roughly $500 million on US advertising for its Wegovy and Ozempic medications in the first nine months of 2025, over double what Eli Lilly (LLY) spent for its rival drugs, Reuters reported Wednesday, citing data from MediaRadar.
Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.